Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...

Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

Merck (MRK) is a well-known global healthcare company that develops and sells medicines, vaccines, and animal health products. The company focuses on areas like cancer treatments, infectious diseases, ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Dividend Yield as of December 28: 3.30% Merck & Co., Inc. (NYSE:MRK) is a global healthcare company operating through two segments – Pharmaceutical and Animal Health. The Pharmaceutical segment ...